Exagen Inc. (NASDAQ:XGN) is set to release its quarterly earnings with an expected EPS of -$0.20 and projected revenue of $14.55 million.
The company announced a public offering of 3.35 million shares at $5.25 each, aiming to raise $17.6 million before expenses.
Despite financial challenges indicated by a negative P/E ratio and negative operating cash flow, Exagen shows strong liquidity with a current ratio of 2.32.
Exagen Inc. (NASDAQ:XGN) is a key player in the field of autoimmune testing solutions. The company is preparing to release its quarterly earnings on May 12, 2025. Wall Street analysts predict an earnings per share (EPS) of -$0.20, with projected revenue of around $14.55 million. This comes amid Exagen’s recent public offering of common stock, which is expected to generate significant capital.
The public offering involves 3.35 million shares priced at $5.25 each, potentially raising $17.6 million before expenses. This move is part of Exagen’s strategy to bolster its financial position. The offering is set to close on May 9, 2025, as highlighted by Canaccord Genuity, the sole bookrunner. This capital influx could help address the company’s current financial challenges.
Exagen’s financial metrics reveal some hurdles. The company has a negative P/E ratio of -7.37, indicating negative earnings. Despite this, the price-to-sales ratio of 1.95 suggests investors are still willing to invest nearly $1.95 for every dollar of sales. This reflects a certain level of confidence in Exagen’s sales potential despite current earnings issues.
The enterprise value to sales ratio of 1.85 shows a relatively efficient valuation in terms of sales. However, the enterprise value to operating cash flow ratio of -7.02 highlights negative operating cash flow, a concern for potential investors. The earnings yield of -13.57% further underscores the financial challenges Exagen faces.
Despite these challenges, Exagen maintains a moderate debt-to-equity ratio of 0.79, indicating a balanced approach to leveraging debt. The current ratio of 2.32 suggests a strong liquidity position, meaning the company can comfortably cover its short-term liabilities. This financial stability could be crucial as Exagen navigates its upcoming earnings release and public offering.
